Literature DB >> 32119934

Thiol-mediated and catecholamine-enhanced multimerization of a cerebrovascular disease enriched fragment of NOTCH3.

Kelly Z Young1, Naw May P Cartee2, Magdalena I Ivanova2, Michael M Wang3.   

Abstract

Cerebral small vessel disease is a common condition linked to dementia and stroke. As an age-dependent brain pathology, cerebral SVD may share molecular processes with core neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Many neurodegenerative diseases feature abnormal protein accumulation and aberrant protein folding, resulting in multimerization of specific proteins. We investigated if a small NOTCH3 N-terminal fragment (NTF) that co-registers with pathologically affected cells in the inherited SVD, CADASIL, is capable of multimerization. We also characterized endogenous small molecule vascular enhancers and inhibitors of multimerization. NTF multimerizes spontaneously and also forms conjugates with vascular catecholamines, including dopamine and norepinephrine, which avidly promote multimerization of the protein. Inhibition of catecholamine-dependent multimerization by vitamin C and reversal by reducing agents implicate an essential role of oxidation in NTF multimerization. Antibodies that react with degenerating arteries in CADASIL tissue preferentially bind to multimerized forms of NTF. These studies suggest that multimerization of proteins in the aging brain is not restricted to neuronal molecules and may participate in age-dependent vascular pathology. Published by Elsevier Inc.

Entities:  

Keywords:  CADASIL; Catecholamines; Cysteine residues; Dopamine; NOTCH3; Norepinephrine; Protein oligomerization; Proteinopathies; Small vessel disease; Vascular dementia

Mesh:

Substances:

Year:  2020        PMID: 32119934      PMCID: PMC7146869          DOI: 10.1016/j.expneurol.2020.113261

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  51 in total

1.  Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis.

Authors:  Marco Duering; Anna Karpinska; Stefanie Rosner; Franziska Hopfner; Martin Zechmeister; Nils Peters; Elisabeth Kremmer; Christof Haffner; Armin Giese; Martin Dichgans; Christian Opherk
Journal:  Hum Mol Genet       Date:  2011-05-30       Impact factor: 6.150

Review 2.  Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover.

Authors:  M Esler; G Jennings; P Korner; I Willett; F Dudley; G Hasking; W Anderson; G Lambert
Journal:  Hypertension       Date:  1988-01       Impact factor: 10.190

3.  Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species.

Authors:  B Fornstedt; E Rosengren; A Carlsson
Journal:  Neuropharmacology       Date:  1986-04       Impact factor: 5.250

4.  Characterization of hippocampal norepinephrine release as measured by microdialysis perfusion: pharmacological and behavioral studies.

Authors:  E D Abercrombie; R W Keller; M J Zigmond
Journal:  Neuroscience       Date:  1988-12       Impact factor: 3.590

5.  The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients.

Authors:  A Joutel; F Andreux; S Gaulis; V Domenga; M Cecillon; N Battail; N Piga; F Chapon; C Godfrain; E Tournier-Lasserve
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

6.  Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson's disease.

Authors:  Raymond S Schwartz; Glenda M Halliday; Derrick Soh; Dennis J Cordato; Jillian J Kril
Journal:  J Clin Neurosci       Date:  2018-10-14       Impact factor: 1.961

7.  Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical.

Authors:  S Ito; K Fujita
Journal:  Biochem Pharmacol       Date:  1982-09-15       Impact factor: 5.858

8.  Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase.

Authors:  Y Xu; A H Stokes; R Roskoski; K E Vrana
Journal:  J Neurosci Res       Date:  1998-12-01       Impact factor: 4.164

9.  Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.

Authors:  M M Ruchoux; D Guerouaou; B Vandenhaute; J P Pruvo; P Vermersch; D Leys
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

10.  Biochemical characterization and cellular effects of CADASIL mutants of NOTCH3.

Authors:  He Meng; Xiaojie Zhang; Genggeng Yu; Soo Jung Lee; Y Eugene Chen; Igor Prudovsky; Michael M Wang
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

View more
  5 in total

1.  Electrophilic and Drug-Induced Stimulation of NOTCH3 N-terminal Fragment Oligomerization in Cerebrovascular Pathology.

Authors:  K Z Young; N M P Cartee; S J Lee; S G Keep; M I Ivanova; Michael M Wang
Journal:  Transl Stroke Res       Date:  2021-05-03       Impact factor: 6.829

2.  Trans-Reduction of Cerebral Small Vessel Disease Proteins by Notch-Derived EGF-like Sequences.

Authors:  Naw May Pearl Cartee; Soo Jung Lee; Kelly Z Young; Xiaojie Zhang; Michael M Wang
Journal:  Int J Mol Sci       Date:  2022-03-27       Impact factor: 6.208

3.  Binding of omeprazole to protein targets identified by monoclonal antibodies.

Authors:  Naw May Pearl Cartee; Michael M Wang
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

Review 4.  Overlapping Protein Accumulation Profiles of CADASIL and CAA: Is There a Common Mechanism Driving Cerebral Small-Vessel Disease?

Authors:  Kelly Z Young; Gang Xu; Simon G Keep; Jimo Borjigin; Michael M Wang
Journal:  Am J Pathol       Date:  2020-12-30       Impact factor: 4.307

5.  Fibrinogen is an Independent Risk Factor for White Matter Hyperintensities in CADASIL but not in Sporadic Cerebral Small Vessel Disease Patients.

Authors:  Xingfang Guo; Bin Deng; Lizi Zhong; Fen Xie; Qing Qiu; Xiaobo Wei; Wenya Wang; Jiangping Xu; Ganqiang Liu; Wong Peter Tsun Hon; Midori A Yenari; Shuzhen Zhu; Qing Wang
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.